Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment
source: Blood
year: 2017
authors: Berthaut I, Bachir D, Kotti S, Chalas C, Stankovic K, Eustache F, Ravel C, Habibi A, Brailly-Tabard S, Lévy-Dutel L, Bleibtreu A, Simon T, Galactéros F, Lionnet F, Mandelbaum J
summary/abstract:The prognosis of sickle cell anemia (SCA), initially disastrous in the severe forms of the disease, has greatly improved, leading to increased life expectancy. More than 95% to 99% of the children diagnosed with SCA in developed countries will become young adults, reaching reproductive age and able to consider having children of their own. Hydroxyurea (HU) is the main therapy that has considerably modified the prognosis of SCA, allowing, with good compliance, a substantial decrease in morbidity and mortality and significant improvement in quality of life.
Only 3 groups, including our own, have reported the potentially detrimental effect of HU on sperm parameters, when initiated in adult patients. These retrospective studies were performed among as few as 8 participants, without any comparative semen assessment before initiation of HU in 7 participants. On the basis of this observation, a prospective multicenter study was designed to assess the effect of 6 months of HU treatment (representing 2 complete cycles of spermatogenesis) on total sperm count (TSC; millions per ejaculate) in 35 men with severe forms of SCA.
organization: Université Paris 06, France; Université Paris 12, France; Université Paris 05, France; Hôpital Tenon, Université Paris 13, France; Centre Hospitalier Universitaire de Rennes, France; Université Paris Sud, France; Université Paris 07, FranceDOI: 10.1182/blood-2017-03-771857
read more full text
+myBinderRelated Content
-
A Conversation on Hydroxyurea: Insights and Information for the Sickle Cell Communityhttps://www.youtube.com/watch?v=Y6fmJn-5...
-
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm countSix months of hydroxyurea therapy detrim...
-
Prevention of Conversion to Abnormal Transcranial Doppler With Hydroxyurea in Sickle Cell Anemia: A Phase III Intern...Children with sickle cell anemia (SCA) a...
-
Sickle Cell Disease and SexualitySeveral diseases can be spread when peop...
-
How a Man and Woman, Both with a Sickle Cell Anemia Mutation, Had a Healthy ChildA man and woman who are both carriers of...
-
How to Talk to Your Child About Hydroxyureahttps://www.youtube.com/watch?v=_apTt2j0...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.